drugset / Trial / NCT01336218

Effects of Administration of Fostamatinib on Blood Concentrations of Rifampicin in Healthy Subjects.

NCT01336218

Phase 1 Completed 15 enrolled AstraZeneca
Non-randomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to investigate the drug interaction between fostamatinib and rifampicin by comparing the safety, tolerability and plasma concentration of fostamatinib when administered alone and with rifampicin in healthy subjects

Timeline

Start
2011-04
Primary completion
2011-07
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Fostamatinib Small molecule 150 mg Oral
Subject Rifampin Small molecule 600 mg Oral

Indications